The Time Has Come: 4 Gene Therapy Stocks to Buy, 1 to Avoid - Barron's

Barron's
The Time Has Come: 4 Gene Therapy Stocks to Buy, 1 to Avoid
Barron's
As Barron's has warned repeatedly over the years, small drug companies with high-flying stocks can turn on a dime. The FDA remains unpredictable, and even a truly innovative drug can flop commercially if insurers don't cover it, doctors don't prescribe ...

and more »

(Source: Market News via Google News)